Overcoming tumor escape by breaking IFNγ resistance in RMS is, therefore, worth to be tested as an adjunct to immunotherapies based on vaccination or adoptive transfer of tumor-reactive cytotoxic effector cells. The gene discussed is IFNG; the disease is neoplasm.